Data from - Curated by EPG Health - Date added 22 March 2019

The European Lung Cancer Congress (ELCC) will be held in Geneva, Switzerland from 10th - 13th April 2019.

ELCC is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, working together to advance science, disseminate education and improve the practice of lung cancer specialists worldwide.

Join thousands of delegates at this ELCC 2019 meeting which is designed to discuss the science, education and practice of treating lung cancer. ELCC is the premier meeting for professionals in the field.

A number of topics will be discussed at ELCC 2019 including:

  • I-O combinations and biomarkers
  • Molecular diagnostics and therapies
  • Early detection of lung cancer
  • Multidisciplinary treatment of locally advanced disease
  • Sequencing treatment in advanced disease
  • SCLC and mesothelioma

Further details can be found on the ELCC 2019 website here.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

CDK 4/6 inhibitors in metastatic breast cancer

CDK 4/6 inhibitors in metastatic breast cancer

The CDK 4/6 Inhibitors in Metastatic Breast Cancer Learning Zone provides insights and information for metastatic breast cancer (mBC) and CDK 4/6 signalling. This includes the burden and pathophysiology of the disease, the role of CDK 4/6 in cell proliferation and an overview of the CDK 4/6 inhibitors that have been approved for the management of mBC.

Load more

Related Content